Acid has antiproliferative effects in nonneoplastic Barrett's epithelial cells

Linda A. Feagins, Hui Ying Zhang, Kathy Hormi-Carver, Mizael H. Quinones, Deena Thomas, Xi Zhang, Lance S. Terada, Stuart J. Spechler, Ruben D. Ramirez, Rhonda F. Souza

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

OBJECTIVES: For patients with Barrett's esophagus, physicians commonly prescribe antisecretory medications in dosages above those required to heal reflux esophagitis because acid has been shown to have proproliferative and antiapoptotic effects on Barrett's cancer cells and on Barrett's mucosal explants. For a number of reasons, these model systems may not be ideal for determining the effects of acid on benign Barrett's epithelial cells, however. We studied the effects of acid on proliferation and apoptosis in a nonneoplastic, telomerase-immortalized Barrett's epithelial cell line. METHODS: Barrett's cells were treated with two 3-minute exposures to acidic media. Cell growth was determined using cell counts, proliferation was studied by flow cytometry, cell viability was determined by trypan blue staining, and apoptosis was assessed by TUNEL and Annexin V. The expression levels of p53 and p21 were determined by Western blotting. p53 siRNA was used to study the effect of p53 inhibition on total cell numbers after acid exposure. RESULTS: Acid exposure significantly decreased total cell numbers at 24 h without affecting either cell viability or apoptosis. Acid exposure resulted in cell cycle prolongation that was associated with greater expression of p53, but not p21. The acid-induced decrease in total cell numbers was abolished by p53 RNAi. CONCLUSIONS: Acid exposure has p53-mediated, antiproliferative effects in nonneoplastic Barrett's epithelial cells. These findings contradict the results of prior in vitro and ex vivo studies. We speculate that the prescription of antisecretory medications in dosages beyond those required to heal gastroesophageal reflux disease (GERD) symptoms and endoscopic signs could be detrimental. Controlled, prospective clinical trials are needed to determine the optimal level of acid suppression for patients with Barrett's esophagus.

Original languageEnglish (US)
Pages (from-to)10-20
Number of pages11
JournalAmerican Journal of Gastroenterology
Volume102
Issue number1
DOIs
StatePublished - Jan 2007

Fingerprint

Epithelial Cells
Acids
Cell Count
Barrett Esophagus
Apoptosis
Cell Survival
Peptic Esophagitis
Trypan Blue
Annexin A5
Telomerase
Controlled Clinical Trials
In Situ Nick-End Labeling
Gastroesophageal Reflux
RNA Interference
Small Interfering RNA
Signs and Symptoms
Prescriptions
Cell Cycle
Flow Cytometry
Western Blotting

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Acid has antiproliferative effects in nonneoplastic Barrett's epithelial cells. / Feagins, Linda A.; Zhang, Hui Ying; Hormi-Carver, Kathy; Quinones, Mizael H.; Thomas, Deena; Zhang, Xi; Terada, Lance S.; Spechler, Stuart J.; Ramirez, Ruben D.; Souza, Rhonda F.

In: American Journal of Gastroenterology, Vol. 102, No. 1, 01.2007, p. 10-20.

Research output: Contribution to journalArticle

Feagins, Linda A. ; Zhang, Hui Ying ; Hormi-Carver, Kathy ; Quinones, Mizael H. ; Thomas, Deena ; Zhang, Xi ; Terada, Lance S. ; Spechler, Stuart J. ; Ramirez, Ruben D. ; Souza, Rhonda F. / Acid has antiproliferative effects in nonneoplastic Barrett's epithelial cells. In: American Journal of Gastroenterology. 2007 ; Vol. 102, No. 1. pp. 10-20.
@article{d0b3b39966b24562aed5e8e64ccbd71d,
title = "Acid has antiproliferative effects in nonneoplastic Barrett's epithelial cells",
abstract = "OBJECTIVES: For patients with Barrett's esophagus, physicians commonly prescribe antisecretory medications in dosages above those required to heal reflux esophagitis because acid has been shown to have proproliferative and antiapoptotic effects on Barrett's cancer cells and on Barrett's mucosal explants. For a number of reasons, these model systems may not be ideal for determining the effects of acid on benign Barrett's epithelial cells, however. We studied the effects of acid on proliferation and apoptosis in a nonneoplastic, telomerase-immortalized Barrett's epithelial cell line. METHODS: Barrett's cells were treated with two 3-minute exposures to acidic media. Cell growth was determined using cell counts, proliferation was studied by flow cytometry, cell viability was determined by trypan blue staining, and apoptosis was assessed by TUNEL and Annexin V. The expression levels of p53 and p21 were determined by Western blotting. p53 siRNA was used to study the effect of p53 inhibition on total cell numbers after acid exposure. RESULTS: Acid exposure significantly decreased total cell numbers at 24 h without affecting either cell viability or apoptosis. Acid exposure resulted in cell cycle prolongation that was associated with greater expression of p53, but not p21. The acid-induced decrease in total cell numbers was abolished by p53 RNAi. CONCLUSIONS: Acid exposure has p53-mediated, antiproliferative effects in nonneoplastic Barrett's epithelial cells. These findings contradict the results of prior in vitro and ex vivo studies. We speculate that the prescription of antisecretory medications in dosages beyond those required to heal gastroesophageal reflux disease (GERD) symptoms and endoscopic signs could be detrimental. Controlled, prospective clinical trials are needed to determine the optimal level of acid suppression for patients with Barrett's esophagus.",
author = "Feagins, {Linda A.} and Zhang, {Hui Ying} and Kathy Hormi-Carver and Quinones, {Mizael H.} and Deena Thomas and Xi Zhang and Terada, {Lance S.} and Spechler, {Stuart J.} and Ramirez, {Ruben D.} and Souza, {Rhonda F.}",
year = "2007",
month = "1",
doi = "10.1111/j.1572-0241.2006.01005.x",
language = "English (US)",
volume = "102",
pages = "10--20",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Acid has antiproliferative effects in nonneoplastic Barrett's epithelial cells

AU - Feagins, Linda A.

AU - Zhang, Hui Ying

AU - Hormi-Carver, Kathy

AU - Quinones, Mizael H.

AU - Thomas, Deena

AU - Zhang, Xi

AU - Terada, Lance S.

AU - Spechler, Stuart J.

AU - Ramirez, Ruben D.

AU - Souza, Rhonda F.

PY - 2007/1

Y1 - 2007/1

N2 - OBJECTIVES: For patients with Barrett's esophagus, physicians commonly prescribe antisecretory medications in dosages above those required to heal reflux esophagitis because acid has been shown to have proproliferative and antiapoptotic effects on Barrett's cancer cells and on Barrett's mucosal explants. For a number of reasons, these model systems may not be ideal for determining the effects of acid on benign Barrett's epithelial cells, however. We studied the effects of acid on proliferation and apoptosis in a nonneoplastic, telomerase-immortalized Barrett's epithelial cell line. METHODS: Barrett's cells were treated with two 3-minute exposures to acidic media. Cell growth was determined using cell counts, proliferation was studied by flow cytometry, cell viability was determined by trypan blue staining, and apoptosis was assessed by TUNEL and Annexin V. The expression levels of p53 and p21 were determined by Western blotting. p53 siRNA was used to study the effect of p53 inhibition on total cell numbers after acid exposure. RESULTS: Acid exposure significantly decreased total cell numbers at 24 h without affecting either cell viability or apoptosis. Acid exposure resulted in cell cycle prolongation that was associated with greater expression of p53, but not p21. The acid-induced decrease in total cell numbers was abolished by p53 RNAi. CONCLUSIONS: Acid exposure has p53-mediated, antiproliferative effects in nonneoplastic Barrett's epithelial cells. These findings contradict the results of prior in vitro and ex vivo studies. We speculate that the prescription of antisecretory medications in dosages beyond those required to heal gastroesophageal reflux disease (GERD) symptoms and endoscopic signs could be detrimental. Controlled, prospective clinical trials are needed to determine the optimal level of acid suppression for patients with Barrett's esophagus.

AB - OBJECTIVES: For patients with Barrett's esophagus, physicians commonly prescribe antisecretory medications in dosages above those required to heal reflux esophagitis because acid has been shown to have proproliferative and antiapoptotic effects on Barrett's cancer cells and on Barrett's mucosal explants. For a number of reasons, these model systems may not be ideal for determining the effects of acid on benign Barrett's epithelial cells, however. We studied the effects of acid on proliferation and apoptosis in a nonneoplastic, telomerase-immortalized Barrett's epithelial cell line. METHODS: Barrett's cells were treated with two 3-minute exposures to acidic media. Cell growth was determined using cell counts, proliferation was studied by flow cytometry, cell viability was determined by trypan blue staining, and apoptosis was assessed by TUNEL and Annexin V. The expression levels of p53 and p21 were determined by Western blotting. p53 siRNA was used to study the effect of p53 inhibition on total cell numbers after acid exposure. RESULTS: Acid exposure significantly decreased total cell numbers at 24 h without affecting either cell viability or apoptosis. Acid exposure resulted in cell cycle prolongation that was associated with greater expression of p53, but not p21. The acid-induced decrease in total cell numbers was abolished by p53 RNAi. CONCLUSIONS: Acid exposure has p53-mediated, antiproliferative effects in nonneoplastic Barrett's epithelial cells. These findings contradict the results of prior in vitro and ex vivo studies. We speculate that the prescription of antisecretory medications in dosages beyond those required to heal gastroesophageal reflux disease (GERD) symptoms and endoscopic signs could be detrimental. Controlled, prospective clinical trials are needed to determine the optimal level of acid suppression for patients with Barrett's esophagus.

UR - http://www.scopus.com/inward/record.url?scp=33846079689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846079689&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.2006.01005.x

DO - 10.1111/j.1572-0241.2006.01005.x

M3 - Article

C2 - 17266684

AN - SCOPUS:33846079689

VL - 102

SP - 10

EP - 20

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 1

ER -